{"product_id":"mygn-marketing-mix","title":"(MYGN) Myriad Genetics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Myriad Genetics, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategies and how they drive market positioning and sales; it’s designed for fast marketing research and strategic planning. The page shows a real preview\/sample of the report so you can review style and content—purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk Hereditary Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk Hereditary Cancer Test is Myriad Genetics, Inc.'s core oncology test: a 48-gene germline DNA sequencing panel for inherited cancer risk. It screens across multiple tumor types to find hereditary cancer predisposition early. That helps clinicians make faster screening, prevention, and family-testing decisions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRACAnalysis CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRACAnalysis CDx is Myriad Genetics, Inc.'s FDA-approved companion diagnostic for BRCA1 and BRCA2 variants, used in metastatic breast, ovarian, pancreatic, and prostate cancers to help pick treatment, including PARP inhibitors. BRCA1\/2 mutations appear in about 5%-10% of breast cancers and 10%-15% of ovarian cancers, which supports steady clinical demand. The test links diagnosis to therapy, making it a core precision-oncology product for Myriad Genetics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyChoice CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyChoice CDx is a tumor-based homologous recombination deficiency assay that helps guide ovarian cancer care, where the American Cancer Society estimated 20,890 new U.S. cases and 12,730 deaths in 2025. It supports precision medicine by identifying patients more likely to benefit from targeted therapies, including PARP inhibitors, which makes the test clinically useful at the point of treatment choice. For Myriad Genetics, Inc., the product is a differentiated diagnostic asset built for companion-diagnostic use in a high-need oncology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProlaris and EndoPredict\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProlaris and EndoPredict are RNA expression-based prognostic tests that help estimate tumor aggressiveness in prostate and breast cancer, so physicians can match treatment intensity to disease biology. Myriad Genetics positions them as decision tools that can reduce overtreatment and support more precise care.\u003c\/p\u003e\n\u003cp\u003eThese tests sit in the high-value oncology diagnostics segment, where each result can shape surgery, radiation, or hormone therapy choices. In Myriad Genetics latest reported mix, oncology products remain a core revenue driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProlaris: prostate cancer prognosis\u003c\/li\u003e\n\u003cli\u003eEndoPredict: breast cancer prognosis\u003c\/li\u003e\n\u003cli\u003eRNA expression analysis\u003c\/li\u003e\n\u003cli\u003eGuides treatment intensity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrequel, Foresight, GeneSight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrequel is a prenatal screening test, Foresight is a carrier screen, and GeneSight is a psychotropic medication test. Together they push Myriad Genetics beyond oncology into women’s health and mental health, covering decision points from preconception to treatment selection.\u003c\/p\u003e\n\u003cp\u003eThis broader mix widens the addressable patient base and helps Myriad serve multiple clinicians, not just oncologists. GeneSight has been ordered for over 2 million patients, showing scale in medication guidance.\u003c\/p\u003e\n\u003cp\u003eThat portfolio also adds cross-sell value: one Company can touch family planning, pregnancy risk, and psychiatric prescribing. For the 4P mix, the product line is a clear differentiator because it spans the full patient lifecycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrequel: prenatal screening\u003c\/li\u003e\n\u003cli\u003eForesight: carrier screening\u003c\/li\u003e\n\u003cli\u003eGeneSight: psychotropic guidance\u003c\/li\u003e\n\u003cli\u003eReach: preconception to psychiatry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Cancer Tests Lead, With Psychiatry and Reproductive Health Growing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. product mix is led by oncology diagnostics: MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict.\u003c\/p\u003e\n\u003cp\u003eThese tests cover inherited risk, companion diagnostics, and prognosis, helping guide treatment for breast, ovarian, prostate, and pancreatic cancer.\u003c\/p\u003e\n\u003cp\u003eGeneSight, Prequel, and Foresight widen the portfolio into psychiatry and reproductive health.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003eHereditary cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003ePsychiatry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Myriad Genetics, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Myriad Genetics’ 4Ps into a quick, clear snapshot that helps teams spot positioning gaps fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed studies to verify Myriad Genetics’ market, pricing, and clinical claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States clinical market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. sells into the United States clinical market through physicians, hospitals, and lab workflows, not retail shelves. Its tests are ordered in care settings across all 50 states, so access depends on clinician demand, reimbursement, and payer contracts. This channel fits genetic testing, where the \"place\" is the clinical pathway from order to result. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. sells in international markets, which extends its precision-medicine reach beyond the U.S. In FY2025, the Company reported $837.5 million in revenue, and foreign demand can add growth when local rules allow it. Access still depends on country-by-country regulatory clearance and reimbursement, so uptake can vary a lot by market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and specialist channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics routes most testing through physicians, oncologists, OB-GYNs, and mental health prescribers, so the product sits inside the care path, not after it. This fits a clinical market where test orders are tied to treatment choices, and it helps place testing where the decision happens: at the point of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealth system and lab partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses health system and lab partnerships to widen access to germline and somatic tumor testing. Alliances with Illumina and Intermountain Precision Genomics support broader test reach, stronger workflow fit, and faster market entry across provider networks.\u003c\/p\u003e\n\u003cp\u003eThese ties help Myriad keep its tests close to the point of care, which can lift adoption in oncology and hereditary cancer screening. The model matters because myRisk and myChoice CDx depend on both clinical trust and lab scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIllumina expands testing capability\u003c\/li\u003e\n\u003cli\u003eIntermountain boosts provider access\u003c\/li\u003e\n\u003cli\u003eSupports germline and somatic testing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCentralized laboratory model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses a centralized laboratory model for most genetic tests, which keeps complex molecular diagnostics in specialized lab sites and supports tighter quality control, faster turnaround, and consistent reporting. This setup fits high-complexity assays better than a wide local-network model because one lab platform can standardize workflow and review.\u003c\/p\u003e\n\u003cp\u003eIt also helps Myriad Genetics, Inc. scale test volumes while keeping results comparable across indications like hereditary cancer and prenatal testing. In a diagnostics business, that consistency matters as much as speed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized processing improves quality control\u003c\/li\u003e\n\u003cli\u003eStandardized reporting supports clinician trust\u003c\/li\u003e\n\u003cli\u003eBest fit for complex molecular tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad Genetics: Care-Path Testing Drives $837.5M Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. places testing inside the care path: physicians and health systems order tests, and results return through centralized labs. That model supported FY2025 revenue of $837.5 million, while U.S. access, reimbursement, and international rules still shape where demand converts to sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$837.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess model\u003c\/td\u003e\n\u003ctd\u003ePhysician and health system orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperations\u003c\/td\u003e\n\u003ctd\u003eCentralized laboratory delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eMyriad Genetics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Myriad Genetics, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable document covering Product, Price, Place, and Promotion with actionable insights and examples tailored to Myriad’s diagnostics business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics promotes its tests with clinical utility data and peer-reviewed science, which matters because physicians and payers often want proof that a test changes care, not just that it works in the lab. Its messaging centers on decision support and patient impact, helping clinicians choose treatment sooner and with more confidence. In diagnostics, evidence drives reimbursement and adoption, so this proof-first approach is a core sales tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician education programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysician education is Myriad Genetics, Inc.\"s main promotion tool because its tests are ordered by healthcare professionals. In oncology, prenatal care, and psychiatric pharmacogenomics, training on indications and result use matters: 1 in 8 U.S. women face breast cancer, and PGx can cut adverse drug reactions by 30% to 40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic alliance announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses strategic alliances as promotion, with at least 2 visible partners, Illumina and Intermountain Precision Genomics, to boost credibility and reach. These deals help signal product integration, which can speed adoption in clinical labs and broaden market access. For investors, partner-led promotion matters because it supports trust without heavy brand spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can use medical congresses to share fresh clinical data and study results with specialists who shape test use. Major meetings matter: ASCO 2025 drew more than 40,000 oncology professionals, giving Myriad Genetics, Inc. direct access to high-impact prescribers.\u003c\/p\u003e\n\u003cp\u003eThis channel supports trust, speeds adoption, and keeps the portfolio visible beside peer-reviewed science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShows new data fast\u003c\/li\u003e\n\u003cli\u003eReaches key specialists\u003c\/li\u003e\n\u003cli\u003eSupports test adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic relations and investor communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses press releases, earnings materials, and corporate updates to keep investors informed on product launches, reimbursement progress, and strategy. In its 2025 reporting cycle, this channel mix helped support market awareness and credibility as the company worked through payer coverage and growth updates. One line: it is built to move news fast and keep stakeholders aligned.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePress releases on launches\u003c\/li\u003e\n\u003cli\u003eEarnings updates on growth\u003c\/li\u003e\n\u003cli\u003eReimbursement progress for coverage\u003c\/li\u003e\n\u003cli\u003eSignals strategic direction clearly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Evidence-Led Promotion Drives Reimbursement and Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses evidence-led promotion: physician education, peer-reviewed data, congresses, and payer-facing proof. In 2025, it reported $837.5M revenue, so sales support matters; strong reimbursement and clinical adoption are the core promotion goals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eMedical evidence\u003c\/td\u003e\n\u003ctd\u003eBuild trust\u003c\/td\u003e\n\u003ctd\u003e$837.5M revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTest-by-test pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics’ pricing is test-by-test, not one flat rate: each assay is set by complexity, clinical use, and payer coverage, so economics differ across hereditary cancer, prenatal, and pharmacogenomic tests. In FY2025, that mix and reimbursement flow mattered more than list price, with realized price varying by assay. This is a per-test model, not a bundle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer reimbursement is the main price lever for Myriad Genetics, Inc., because insurer coverage decides whether patients pay near $0 or face hundreds of dollars in out-of-pocket costs. In molecular diagnostics, medical-necessity rules vary by plan and can change access fast, so coverage is as important as list price.\u003c\/p\u003e\n\u003cp\u003eMyriad Genetics, Inc. must win favorable payer policies to protect volume and margins. Recent U.S. payer shifts in genetic testing have tightened prior-authorization and evidence demands, which makes reimbursement the real price gatekeeper.\u003c\/p\u003e\n\u003cp\u003eThat means the same test can sell at one price but clear at another, based on payer contracts, coding, and clinical-policy reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance and network contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. prices tests through negotiated payer contracts, so network status can sharply change what patients pay and what the company actually collects. In-network coverage usually lowers out-of-pocket costs and makes tests easier to order, while out-of-network claims can mean higher patient bills and lower realized revenue. Contracted reimbursement is key to broader adoption because it gives doctors and payers clearer payment rules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSelf-pay and patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can face self-pay demand when payer coverage is limited, so billing help matters. Patient support programs and financial assistance can lower out-of-pocket cost spikes for clinically useful tests, which helps keep access from slipping when coverage is narrow. That matters in a market where even a small cost gap can block uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSelf-pay fills coverage gaps.\u003c\/li\u003e\n\u003cli\u003eSupport tools reduce cost barriers.\u003c\/li\u003e\n\u003cli\u003eAccess improves for needed tests.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based diagnostic pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. prices tests on clinical utility, not lab volume, so high-complexity assays and companion diagnostics can carry higher value when they change treatment decisions.\u003c\/p\u003e\n\u003cp\u003eThis fits precision medicine, where payers want proof that a test improves care and cuts downstream costs.\u003c\/p\u003e\n\u003cp\u003eLatest reported annual filings show revenue still driven by these evidence-backed tests, not commodity pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice reflects treatment impact.\u003c\/li\u003e\n\u003cli\u003ePayer evidence drives access.\u003c\/li\u003e\n\u003cli\u003eCompanion tests earn premium value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad's Real Price Is Set by Payers, Not Lists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses test-level pricing, so the real price is set by payer reimbursement, prior authorization, and contract status, not a single list price. In FY2025, realized price varied by assay, with coverage deciding both patient cost and company cash collected.\u003c\/p\u003e\n\u003cp\u003eSelf-pay support helps fill coverage gaps, but payer policy remains the main gatekeeper for volume and margin. Clinical utility still drives pricing power for higher-value tests.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice driver\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003eSets realized price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract status\u003c\/td\u003e\n\u003ctd\u003eChanges patient cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical utility\u003c\/td\u003e\n\u003ctd\u003eSupports premium pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234719408393,"sku":"mygn-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mygn-marketing-mix.webp?v=1785725813","url":"https:\/\/dcfanalyst.com\/products\/mygn-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}